Health Care [ 3/12 ] | Pharmaceuticals [ 15/75 ]
NASDAQ | Common Stock
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection.
It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis.
It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited.
Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 26 | -0.09 Increased by +30.74% | - |
| Nov 4, 25 | -0.13 Decreased by -18.02% | - |
| Aug 8, 25 | -0.05 Increased by +34.98% | - |
| May 5, 25 | 0.08 Increased by +159.67% | - |
| Mar 3, 25 | -0.14 Increased by +69.31% | - |
| Nov 7, 24 | -0.11 Decreased by -649.50% | - |
| Aug 6, 24 | -0.08 Decreased by -148.06% | - |
| May 7, 24 | -0.14 Decreased by -225.55% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 13.68 M Increased by +31.08% | -1.41 M Increased by +25.85% | Decreased by -10.32% Increased by +43.43% |
| Sep 30, 25 | 8.29 M Decreased by -8.73% | -1.94 M Decreased by -25.69% | Decreased by -23.40% Decreased by -37.72% |
| Jun 30, 25 | 10.84 M Increased by +10.04% | -740.74 K Increased by +31.77% | Decreased by -6.84% Increased by +37.99% |
| Mar 31, 25 | 11.71 M Increased by +37.84% | 1.26 M Increased by +164.59% | Increased by +10.73% Increased by +146.86% |
| Dec 31, 24 | 10.44 M Increased by +11.57% | -1.90 M Increased by +69.75% | Decreased by -18.24% Increased by +72.89% |
| Sep 30, 24 | 9.09 M Decreased by -9.92% | -1.54 M Decreased by -47.15% | Decreased by -16.99% Decreased by -63.35% |
| Jun 30, 24 | 9.85 M Decreased by -9.55% | -1.09 M Decreased by -224.47% | Decreased by -11.02% Decreased by -237.61% |
| Mar 31, 24 | 8.50 M Decreased by -7.88% | -1.95 M Decreased by -1.11 K% | Decreased by -22.90% Decreased by -1.20 K% |